Tech Company Financing Transactions

Vernal Biosciences Funding Round

Vernal Biosciences, based in Burlington, received $21 million from Ampersand Capital Partners, Dynamk Capital and Alloy Therapeutics.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

261 Mountain View Drive
Burlington, VT 05446
USA

Phone

Undisclosed

Website

www.vernal.bio

Email Address

Undisclosed

Overview

We are passionate about channeling Vernal's technology and the hard work of our team to democratize mRNA R&D by making mRNA readily available to more researchers and companies. We believe that science matters more than ever and that mRNA will open many more doors for science to change the lives of humans everywhere. To help fulfill this vision, Vernal is committed to increasing access to the supply of quality mRNA.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Christian Cobaugh

        

Browse more venture capital transactions:

Prev: 6/3/2022: Journera venture capital transaction
Next: 6/3/2022: NuProbe venture capital transaction

Share this article

About Our VC Transactions Data

We do our best to record all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary